

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:771US/SLH

10/074,220

U.S. Department of Patents and Publications for Applicant's

Applicant

Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 12, 2002

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
160	C1	Berchtold <i>et al.</i> , "Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases," <i>FEBS Lett.</i> , 458:424-428, 1999.
	C2	Betto, <i>et al.</i> , "Ecto-ATPase activity of alpha-sarcoglycan (adhalin)" <i>J. Biol. Chem.</i> , 274: 7907-7912, 1999.
	C3	Biederbick, <i>et al.</i> , "A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles," <i>J. Cell Sci.</i> , 112: 2473-2484, 1999.
	C4	Chadwick and Frischauf, "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from <i>Drosophila melanogaster</i> ," <i>Genomics</i> , 50:357-367, 1998.
	C5	Coutinho-Silva <i>et al.</i> , "P2Z/P2X7 receptor-dependent apoptosis of dendritic cells," <i>Am. J. Physiol.</i> 276:C1139-C1147, 1999.
	C6	Di Virgilio, <i>et al.</i> , "Nucleotide receptors: an emerging family of regulatory molecules in blood cells," <i>Blood</i> , 97: 587-600, 2001.
	C7	Dumbrowski <i>et al.</i> , "Ecto-ATPase: an activation marker necessary for effector cell function," <i>Immunol Rev.</i> , 161:111-118, 1998.
160	C8	Effendy, <i>et al.</i> , "Epidermal cytokines in murine cutaneous irritant responses," <i>J. Appl. Toxicol.</i> , 20: 335-341, 2000.

25144084.1

EXAMINER:

Lm Gm

DATE CONSIDERED:

12/21/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:771US/SLH

10/074,220

List of Patents and Publications for Applicant's

Applicant

Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

February 12, 2002

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
46	C9	Enjoji, <i>et al.</i> "Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation," <i>Nat. Med.</i> , 5:1010-1017, 1999.
	C10	Ferrari, <i>et al.</i> "The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release," <i>FASEB J.</i> , 14: 2466-2476, 2000.
	C11	Filippini, <i>et al.</i> , "Extracellular ATP in T-lymphocyte activation: possible role in effector functions," <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 87: 8267-8271, 1990.
	C12	Girolomoni <i>et al.</i> , "Epidermal Langerhans cells are resistant to the permeabilizing effects of extracellular ATP: in vitro evidence supporting a protective role of membrane ATPase," <i>J. Invest Dermatol.</i> , 100:282-287, 1993.
	C13	Heine, <i>et al.</i> , "Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells," <i>Eur J Biochem.</i> , 262(1):102-107, 1999.
	C14	Imai, <i>et al.</i> , "CD39 modulates IL-1 release from activated endothelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 270: 272-278, 2000.
	C15	Knowles and Nagy, "Inhibition of an ecto-ATP-diphosphohydrolase by azide," <i>Eur. J. Biochem.</i> , 262:349-357, 1999.
	C16	Liu <i>et al.</i> "Expression and a role of functionally coupled P2Y receptors in human dendritic cells," <i>FEBS Lett.</i> , 445:402-408, 1999.
	C17	Marriott, <i>et al.</i> , "Extracellular uridine nucleotides initiate cytokine production by murine dendritic cells," <i>Cell. Immunol.</i> , 195:147-156, 1999.
	C18	Matsue <i>et al.</i> , "Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells," <i>Nature Med.</i> , 5:930-937, 1999.
	C19	Matsue, <i>et al.</i> , "Keratinocyte-derived IL-7 serves as a growth factor for dendritic epidermal T-cells in mice," <i>J. Immunol.</i> , 151:6012-6019, 1993.
	C20	Mummert, <i>et al.</i> , "Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking," <i>J. Exp. Med.</i> , 192:769-779, 2000.
46	C21	Mutini <i>et al.</i> , "Mouse dendritic cells express the P2X ₇ purinergic receptor: characterization and possible participation in antigen presentation," <i>J. Immunol.</i> , 163:1958-1965, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

12/21/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:771US/SLHSerial No.
10/074,220

List of Patents and Publications for Applicant's

Applicant
Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
February 12, 2002Group:
UnknownU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
46	C22	Nihei, <i>et al.</i> , "Pharmacologic properties of P ₂₂ /P2X ₇ receptor characterized in murine dendritic cells: role on the induction of apoptosis," <i>Blood</i> , 96: 996-1005, 2000.
	C23	Ralevic and Burnstock, "Receptors for purines and pyrimidines," <i>Pharmacol. Rev.</i> 50:413-492, 1998.
	C24	Sellers, <i>et al.</i> , "Adenosine nucleotides acting at the human P2Y ₁ receptor stimulate mitogen-activated protein kinases and induce apoptosis," <i>J. Biol. Chem.</i> , 276: 16379-16390, 2001.
	C25	Sevigny, <i>et al.</i> , "Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase," <i>J. Biol. Chem.</i> , 275: 5640-5647, 2000.
	C26	Wang, and Guidotti, "Golgi localization and functional expression of human uridine diphosphatase," <i>J. Biol. Chem.</i> , 273: 11392-11399, 1998.
	C27	Warny, <i>et al.</i> , "P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide," <i>J. Biol. Chem.</i> , 276: 26051-26056, 2001.
	C28	Williams and Jarvis, "Purinergic and pyrimidinergic receptors as potential drug targets," <i>Biochem. Pharmacol.</i> , 59:1173-1185, 2000.
	C29	Xu, <i>et al.</i> , "Successive generation of antigen-presenting, dendritic cell lines from murine epidermis," <i>J. Immunol.</i> , 154:2697-2705, 1995.
	C30	Zhong and Guidotti, "A yeast Golgi E-type ATPase with an unusual membrane topology," <i>J. Biol. Chem.</i> , 274:32704-32711, 1999.
	C31	Ziganshina, <i>et al.</i> , "Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved," <i>Inflamm. Res.</i> , 45: 96-102, 1996.
46	C32	Zinchuk <i>et al.</i> , "Ecto-ATPase activity in cerebellum: implication to the function of synaptic transmission," <i>Brain Res.</i> 815:111-115, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

12/21/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:771US

10/074,220

List of Patents and Publications for Applicant's

Applicant

Tadashi Kumamoto *et al.*

RECEIVED

APR 29 2003

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 12, 2002

Group:

1645

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
44	B1	WO 98/28437	7/2/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
46	C33	Homolya <i>et al.</i> , "Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia," <i>J. Cell Biol.</i> , 150:1349-1359, 2000.
	C34	Kaplan <i>et al.</i> , "Extracellular nucleotides act through P _{2U} purinoceptors to elevate [Ca ²⁺] and enhance basic fibroblast growth factor-induced proliferation in sheep chondrocytes," <i>Endocrinology</i> , 137:4757-4766, 1996.
	C35	Kaplan <i>et al.</i> , "Extracellular nucleotides potentiate the cytosolic Ca ²⁺ , but not cyclic adenosine 3', 5'-monophosphate response to parathyroid hormone in rat osteoblastic cells," <i>Endocrinology</i> , 136:1674-1685, 1995.
46	C36	Narravula <i>et al.</i> , "Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function," <i>J. of Immunology</i> , 165:5262-5268, 2000.

25281397.1

EXAMINER:

DATE CONSIDERED:

12/21/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)